Latest news with #heartvalve
Yahoo
5 days ago
- Business
- Yahoo
Edwards Lifesciences Lifts 2025 Outlook On Strong First Half Performance
Edwards Lifesciences' (NYSE:EW) stock surged Friday following a strong second-quarter 2025 earnings report that saw the medical device innovator surpass revenue and earnings expectations, driven by significant growth across its heart valve therapies. The strong performance prompted the company to raise its full-year sales guidance, signaling renewed momentum in its core markets. The heart devices company reported sales of $1.53 billion on Thursday after hours, beating the consensus of $1.49 billion and within the management guidance of $1.45 billion-$1.53 billion. Sales grew 11.9% or 10.6% adjusted, with strength across all product groups. Edwards Lifesciences reported adjusted earnings of 67 cents, beating the consensus of 62 cents and the management guidance of 59-65 cents per company reported Transcatheter Aortic Valve Replacement (TAVR) sales of $1.1 billion, marking an increase of 8.9% (or 7.8% on a constant currency basis). The company said that TAVR growth for the quarter surpassed their expectations. Transcatheter Mitral and Tricuspid Therapies (TMTT) segments achieved second-quarter sales of $134.5 million, demonstrating a year-over-year growth of 61.9%, or more than 57.1% on a constant currency basis. In the Surgical segment, second-quarter global sales reached $267 million, an increase of 7.7% over the prior year, or 6.8% on a constant currency basis. Outlook 'We are pleased to report strong second quarter results that delivered double-digit sales growth. Based on our better-than-expected first half performance and the many catalysts across our portfolio, we are confident in our full-year outlook and are raising our sales and EPS guidance,' said Bernard Zovighian, CEO. Edwards Lifesciences raised its 2025 sales guidance from $5.70 billion-$6.10 billion to $5.90 billion-$6.10 billion compared to the consensus of $5.91 billion. The company affirms fiscal 2025 adjusted earnings guidance of $2.40-$2.50 per share compared to the consensus of $2.48. Edwards Lifesciences forecasts third-quarter adjusted earnings of 54-60 cents, compared to the consensus of 60 cents, and sales of $1.46 billion, $1.54 billion versus the consensus of $1.48 billion. View more earnings on EW The company is increasing its underlying growth rate guidance for TAVR to 6% to 7%, driven by strong performance, and its sales guidance range for TAVR to $4.3 billion to $4.5 billion. Sales guidance for TMTT and Surgical product groups remains unchanged. Analyst Insights: Goldman Sachs Goldman Sachs said Friday that the second quarter of 2025 marked a key turning point for the company and reinforced its belief that Edwards is on track to achieve steady double-digit revenue growth again. The firm noted that Edwards' core TAVR business is gaining momentum, even though the quarter only partially reflected the impact of the new asymptomatic indication and included just a small boost from Boston Scientific Corporation's (NYSE:BSX) planned market exit. This gives Goldman confidence that the business will operate at a stronger baseline. Analyst David Roman expects Edwards to get back to its previous strong performance over the next few years, with revenue growing over 10% and operating margins above 30%. With this kind of growth, Goldman Sachs believes the stock deserves a higher valuation, more than 30 times its earnings. The analyst maintains the Buy rating, raising the price forecast from $89 to $101. Other Analysts Several leading financial analysts re-evaluated their outlook on Edwards Lifesciences, with a general trend toward increased price forecasts. Baird has maintained a Neutral rating on the company, slightly increasing its price forecast from $78 to $79. Deutsche Bank, on the other hand, reiterates a Buy rating and has significantly raised its price forecast from $85 to $94. Evercore ISI affirms an In-Line rating, with a modest increase in its price forecast from $77 to $80. Wells Fargo continues to maintain an Overweight rating, raising its price forecast from $80 to $84. Similarly, RBC Capital maintains an Outperform rating, lifting its price forecast from $85 to $89. Piper Sandler also keeps an Overweight rating, increasing its price target from $83 to $90. Barclays maintains an Overweight rating and has raised its price forecast from $90 to $95. Finally, a Stifel analyst has reiterated a Buy rating, also increasing the price forecast from $90 to $95. Price Action: EW stock is trading higher by 4.87% to $79.49 at last check Friday. Read Next:Image via Shutterstock Latest Ratings for EW Date Firm Action From To Feb 2022 UBS Upgrades Neutral Buy Jan 2022 Morgan Stanley Maintains Overweight Jan 2022 Raymond James Maintains Outperform View More Analyst Ratings for EW View the Latest Analyst Ratings UNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets. Get the latest stock analysis from Benzinga? EDWARDS LIFESCIENCES (EW): Free Stock Analysis Report This article Edwards Lifesciences Lifts 2025 Outlook On Strong First Half Performance originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
21-07-2025
- Business
- Yahoo
Medtronic's $106m heart valve patent infringement ruling overturned
The US Court of Appeals has overturned a $106.5m ruling wherein a California court jury found that Medtronic infringed on a heart valve replacement method developed by Colibri Heart Valve. Colibri sued Medtronic in 2020, alleging that the medtech giant's Evolut transcatheter aortic valve replacement (TAVR) systems for treating severe aortic stenosis infringed on its patented method for controlled release of replacement heart valves. The Colorado-based company's filing with a California court alleged that Medtronic's systems infringed on its patented method (No. 8,900,294) of partially deploying a replacement valve from the delivery apparatus and recapturing the valve within the delivery apparatus before full deployment if it looks like the positioning will be off. Colibri's lawsuit asserted that Medtronic learned about its patented methods in a 2014 conference call and during a presentation given by Colibri CEO Joseph Horn about its technology to Medtronic's marketing director and senior clinical programme manager. The patent claimed the 'do-over' method of partial deployment could involve pushing out the valve from an outer sheath of the delivery apparatus or retracting the outer sheath to expose the valve. The case went to trial in 2023, with Medtronic attesting that the accused's use of its product involved partial deployment by retracting, not pushing. During the trial, Colibri dropped its initial assertion of 'literal' infringement and relied solely on the doctrine of equivalents to establish patent infringement using the accused method. Medtronic sought judgment as a matter of law (JMOL) to get this change rejected, deeming the entire premise of the lawsuit invalid; however, the invalidity challenge was rejected. Medtronic was subsequently found to have 'induced infringement', with Colibri awarded $106.5m in damages. The overrule from the US Court of Appeals read: 'We now conclude that prosecution history estoppel, based on Colibri's cancelling of a claim to 'retraction' for partial deployment of the replacement valve and Colibri's own recognition of the close linkage of the subject matter of the cancelled and retained claims, bars application of the doctrine of equivalents. We therefore reverse the district court's denial of JMOL of noninfringement.' A Medtronic spokesperson told Reuters that the court outcome 'affirms our longstanding position that Colibri's patent infringement claims lacked merit". Medical Device Network has reached out to Colibri for comment. "Medtronic's $106m heart valve patent infringement ruling overturned" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
27-06-2025
- Health
- Yahoo
New treatment for heart valve disease in the East
Patients received a new treatment for heart valve disease, which did not require riskier open-heart surgery or travel to London. Five people from Cambridgeshire, Essex, Hertfordshire, Peterborough and Suffolk had the minimally invasive procedure at the Royal Papworth Hospital in Cambridge. It saw them treated for aortic valve regurgitation, which is when blood flows the wrong way through the heart, causing breathlessness, chest pain, fatigue and a fluid build-up. Mary Baker, 79, said she received a transcatheter aortic valve implantation (TAVI) on a Monday and was home by teatime on the Wednesday. Ms Baker from Bishop's Stortford in Hertfordshire was treated in May 2025 and said she was "feeling a thousand percent better". It was deemed too risky to fix her leaky heart valve with open heart surgery, so she had a TAVI fitted at the Cambridge hospital. "I used to play golf and go to the gym two to three times a week, but my condition built up gradually, and I was feeling really poorly because my valve was leaking quite badly," she said. "I was so short of breath all the time – I could barely walk a few yards without stopping, and even talking to people was hard." Since her treatment, she had started driving again and planned to get back to playing golf and going to the gym. Royal Papworth Hospital NHS Foundation Trust was the only hospital in the East of England, and one of a few in the UK, using the Trilogy valve technology. Another patient, a 76-year-old woman from Leigh-on-Sea in Essex, also underwent the procedure in May and has noticed a big improvement in her breathing. She explained: "Beforehand, I couldn't walk very far, and I couldn't do quite a few things around the house because I was getting out of breath so quickly. "Having the Trilogy TAVI valve has really improved my quality of life. I've just had a wander around the supermarket and bought some groceries, and I came home and unpacked everything from the car." Dr Charis Costopoulos said: "These patients now can have definitive treatment here. "Previously, people who were deemed inoperable would bounce in and out of hospital with little quality of life between admissions. "It also means that high-risk patients who would otherwise have surgical aortic valve replacement as their only option can now be treated minimally invasively, resulting in reduced hospital length of stay and much quicker recovery." Follow East of England news on X, Instagram and Facebook: BBC Beds, Herts & Bucks, BBC Cambridgeshire, BBC Essex, BBC Norfolk, BBC Northamptonshire or BBC Suffolk. Runner breaks world record after heart surgery AI study collects thousands of heart recordings Woman, 80, undergoes rare three-valve heart op Royal Papworth Hospital NHS Foundation Trust
BBC News
27-06-2025
- Health
- BBC News
East of England heart valve patients undergo less invasive op
Patients received a new treatment for heart valve disease, which did not require riskier open-heart surgery or travel to people from Cambridgeshire, Essex, Hertfordshire, Peterborough and Suffolk had the minimally invasive procedure at the Royal Papworth Hospital in saw them treated for aortic valve regurgitation, which is when blood flows the wrong way through the heart, causing breathlessness, chest pain, fatigue and a fluid Baker, 79, said she received a transcatheter aortic valve implantation (TAVI) on a Monday and was home by teatime on the Wednesday. Ms Baker from Bishop's Stortford in Hertfordshire was treated in May 2025 and said she was "feeling a thousand percent better".It was deemed too risky to fix her leaky heart valve with open heart surgery, so she had a TAVI fitted at the Cambridge hospital."I used to play golf and go to the gym two to three times a week, but my condition built up gradually, and I was feeling really poorly because my valve was leaking quite badly," she said."I was so short of breath all the time – I could barely walk a few yards without stopping, and even talking to people was hard."Since her treatment, she had started driving again and planned to get back to playing golf and going to the Papworth Hospital NHS Foundation Trust was the only hospital in the East of England, and one of a few in the UK, using the Trilogy valve technology. Another patient, a 76-year-old woman from Leigh-on-Sea in Essex, also underwent the procedure in May and has noticed a big improvement in her explained: "Beforehand, I couldn't walk very far, and I couldn't do quite a few things around the house because I was getting out of breath so quickly."Having the Trilogy TAVI valve has really improved my quality of life. I've just had a wander around the supermarket and bought some groceries, and I came home and unpacked everything from the car."Dr Charis Costopoulos said: "These patients now can have definitive treatment here. "Previously, people who were deemed inoperable would bounce in and out of hospital with little quality of life between admissions."It also means that high-risk patients who would otherwise have surgical aortic valve replacement as their only option can now be treated minimally invasively, resulting in reduced hospital length of stay and much quicker recovery." Follow East of England news on X, Instagram and Facebook: BBC Beds, Herts & Bucks, BBC Cambridgeshire, BBC Essex, BBC Norfolk, BBC Northamptonshire or BBC Suffolk.
